AlzeCure publishes new data on Alzstatin from Alzheimer conference

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's presentation regarding the research platform Alzstatin at the Alzheimer's conference 2nd Swedish Meeting for Alzheimer Research, is now available in its entirety on the company's website.

The presentation, entitled Development of novel gamma-secretase modulators for the treatment of Alzheimer's disease, was given by Maria Backlund, Senior Scientist, and contains preclinical data from studies with a new potent small-molecule γ-secretase modulator (GSM) which is part of AlzeCure's research platform Alzstatin.

The results show that the substance, AC-0027875, effectively crosses the blood-brain barrier and reaches the target organ, i.e. the brain, in high concentrations, which is essential for a good pharmacological effect. Furthermore, data show that the potent effect of the substance on γ-secretase led to a reduction in the amount of harmful Aβ42 by more than 50 percent.

Small-molecule GSMs is a class of drugs that exhibit several important properties that make them suitable as a disease-modifying or preventive treatment for presymptomatic Alzheimer's disease.

"Alzstatin is a disease-modifying drug therapy that is being developed to be particularly well-suited for early, preventive treatment of Alzheimer's disease. Treatment with a small-molecule substance such as Alzstatin has advantages in that it can be optimized to cross the blood-brain barrier in an efficient way, something we have also shown in these new preclinical studies", said Martin Jönsson, CEO of AlzeCure Pharma.

The presentation and abstract are available on AlzeCure’s website: (